Authors
Amanda Heard, Rachel T Huynh, Christy R Hagan, Amy E Moran
Published in
Clinical cancer research : an official journal of the American Association for Cancer Research. Jul 14, 2026. Epub Jul 14, 2026.
Abstract
Cancer immunotherapy treatment has revolutionized cancer care. Of the many FDA approved immunotherapies, immune checkpoint inhibitors are the most widely prescribed, given their utility in treating both solid and hematopoietic diseases and primary and metastatic malignancies. These therapies are dependent on co-opting the body's natural immunity, thus conditions affecting the immune system can also determine therapeutic outcomes for cancer patients. In this review, we examine one such naturally occurring immunomodulatory system: sex steroid hormones. Already thought to play a role in differing outcomes in infectious disease and transplant, sex steroid hormones may be contributing factors to differences in cancer occurrence and immunotherapy success between sexes. We will explore effects of steroid hormones on immune cells, specifically T cells, and the mechanisms through which they exert those effects as reported in the current literature. Androgens and progesterone are reported to exert largely immunosuppressive effects on T cells, by promoting differentiation and expansion of immunosuppressive T cell subpopulations. Interestingly, estrogen has been reported to have both immune activating and immune suppressing effects, both of which have the potential to affect efficacy of immunotherapeutics. Therefore, patient hormonal status should be considered when prescribing immunotherapy for cancer patients.
PMID:
42446663
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0